Chemical proteomic tool for ligand mapping of CYP antitargets: An NMR-compatible 3D QSAR descriptor in the Heme-Based Coordinate System

Journal of Chemical Information and Computer Sciences

Volumn 44, Issue 4, 2004, Pages 1456-1465

  Yao, Huili ^a   Costache, Aurora D ^a   Sem, Daniel S ^a  

^a MARQUETTE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DESIGN; LIGAND MAPPING; REAGENTS; TOXICOLOGY;

ADSORPTION; CHEMICAL BONDS; DRUG DOSAGE; GENES; GENETIC ALGORITHMS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARAMAGNETISM; TOXICITY; X RAY CRYSTALLOGRAPHY;

PROTEINS;

CYTOCHROME P450; HEME; LIGAND;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEOMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICS;

COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; HEME; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROTEOMICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4043136505     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci034208q     Document Type: Article

References (54)

1. Sem, D. S.; Pellecchia, M. NMR in the acceleration of drug discovery Curr. Opin. Drug Discuss. Devel. 2001, 4, 479-493.
2. Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell. 2000, 5, 121-131.
3. Wester, M. R.; Johnson, E. F.; Marques-Soares, C.; Dansette, P. M.; Mansuy, D.; Stout, C. D. Structure of a substrate complex of mammalian cytochrome P450 at 2.3 Å resolution: evidence for multiple substrate binding modes. Biochemistry 2003, 42, 6370-6379.
4. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003, 424, 464-468.
5. Lewis, D. F.; Eddershaw, P. J.; Goldfarb, P. S.; Tarbit, M. H. Molecular modeling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997, 27, 319-339.
6. Lewis, D. F. Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity. Exp. Toxicol. Pathol. 1999, 61, 369-374.
7. de Groot, M. J.; Ackland, M. J.; Home, V. A.; Alex, A. A.; Jones, B. C. Novel approach to predicting P450-mediated drug metabolism: developments of a combined protein and pharmacophore model. J. Med. Chem. 1999, 42, 1515-1524.
8. de Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 1999, 42, 4062-4070.
9. Vermeulen, N. P. Prediction of drug metabolism: the case of cytochrome P450 2D6. Cuir. Top. Med. Chem. 2003, 3, 1227-1239.
10. de Groot, M. J.; Ekins, S. Pharmacophore modelling of cytochromes P450. Adv. Drug Deliv. Rev. 2002, 54, 367-383.
11. Modi, S.; Paine, M. J.; Sutcliffe, M. J.; Lian, L. Y.; Primrose, W. U.; Wolf, C. R.; Roberts, G. C. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 1996, 35, 4540-4550.
12. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
13. Lipinski, C. A.; Lombardo, F.; Dominy, B. M.; Feeny, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26.
14. Klopman, G. Artificial intelligence approach to structure-activity studies. J. Am. Chem. Soc. 1984, 106, 7315-7321.
15. TOPKAT, version 5.01. Oxford Molecular Group, Inc. www. oxmol.com.
16. Sanderson, D. M.; Earnshaw, C. G. Computer prediction of possible toxic action from chemical structure. Hum. Experimental Toxicol. 1991, 10, 261-273.
17. Durham, S. K.; Pearl, G. M. Computational methods to predict drug safety liabilities. Curr. Opin. Drug Discov. Devel. 2001, 4, 110-115.
18. Benigni, R. The first US National Toxicology Program exercise on the prediction of rodent carcinogenicity: definitive results. Mutat. Res. 1997, 387, 35-45.
19. Pearlman, R. S. Metric validation and the receptor relevant subspace concept. J. Chem. Inf. Comput. Sci. 1999, 39, 28-35.
20. Solomon, I.; Bloembergen, N. J. Chem. Phys. 1999, 25, 261.
21. Krugh, T. R. Spin-Label-Induced Nuclear Magnetic Resonance Relaxation Studies of Enzymes. In Spin Labeling: Theory and Applications; Berlinger, L. J., Ed.; Academic Press: New York, 1976.
22. Jardetzky, O.; Roberts, G. C. K. In NMR in Molecular Biology; Academic Press: New York, 1981.
23. Mohr, P. J.; Taylor, B. N. CODATA recommended values of the fundamental physical constants: 1998. Rev. Modern Phys. 2000, 72, 351-495.
24. Wilkens, S. J.; Xia, B.; Volkman, B. F.; Weinhold, F.; Markley, J. L.; Westler, W. M. Inadequacies of the point-dipole approximation for describing electron-nuclear interactions in paramagnetic proteins: hybrid density functional calculations and the analysis of NMR relaxation of high-spin iron(III) rubredoxin. J. Phys. Chem. B 1998, 102, 8300-8305.
25. Graham-Lorence, S. E.; Petersonm, J. A. Structural alignments of P450s and extrapolations to the unknown. Methods Enzymol. 1996, 272, 315-326.
26. Jean, P.; Pothier, J.; Dansette, P. M.; Mansuy, D.; Viari, A. Automated multiple analysis of protein structures: application to homology modeling of cytochromes P450. Proteins 1997, 28, 388-404.
27. Schwede, T.; Kopp, J.; Guex, N.; Peitsch, M. C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 2003, 31, 3381-3385.
28. Guex, N.; Peitsch, M. C. SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modelling. Electrophoresis 1997, 18, 2714-2723.
29. Peitsch, M. C. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling. Biochem. Soc. Trans. 1996, 24, 274-279.
30. Kirton, S. B.; Kemp, C. A.; Tomkinson, N. P.; St-Gallay, S.; Sutcliffe, M. J. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins 2002, 49, 216-231.
31. Halgren, T. A. Merck molecular force field. I Basis, form, scope, parametrization, and performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
32. Halgren, T. A. Merck molecular force field. II van der Waals and electrostatic parameters for intermolecular interactions. J. Comput. Chem. 1996, 17, 520-552.
33. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins and nucleic acids. J. Am. Chem. Soc. 1995, 177, 5179-5197.
34. Page, M. I.; Jencks, W. P. Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. Proc. Natl. Acad. Sci. U.S.A. 1971, 68, 1678-1683.
35. Hansch, C.; Fujita, T. rho-sigma-pi. A Method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 1964, 86, 1616.
36. Hansch, C.; Leo, A. In Exploring QSAR: Fundamentals and Applications in Chemistry and Biology; American Chemical Society: Washington, DC, 1995.
37. Hopfinger, A. J.; Burke, B. J. In Concepts and Applications of Molecular Similarity; Johnson, M. A., Maggiora, C. A., Eds.; Wiley: New York, 1990; p 173.
38. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on the binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
39. Voet, D.; Voet, J. G. In Biochemistry, 2nd ed.; Wiley: Sumerset, NJ, 1995.
40. Poulos, T. L.; Finzel, B. C.; Howard, A. J. High-resolution crystal structure of P450cam. J. Mol. Biol. 1987, 195, 687-700.
41. Lewis, D. F. V.; Lake, B. G.; George, S.; Dickins, M.; Beresford, A. P.; Eddershaw, P. J.; Tarbit, M. H.; Goldfarb, P. S.; Guengerich, F. P. Molecular modeling of CYP1 family isoforms CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 1999, 139, 53-79.
42. Lewis, D. F. V.; Eddershaw, P. J.; Goldfarb, P. S.; Tarbit, M. H. Molecular modeling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica 1996, 26, 1067-1086.
43. Lewis, D. F. V.; Dickins, M.; Weaver, R. J.; Eddershaw, P. J.; Goldfarb, P. S.; Tarbit, M. H. Molecular modelling of CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C family. Xenobiotica 1998, 28, 235-268.
44. Lewis, D. F. V.; Eddershaw, P. J.; Goldfarb, P. S.; Tarbit, M. H. Molecular modeling of cytochrome P4502D6 (CYP2D6) based on alignment with CYP102: structural studies on specific CYP2D6 metabolism. Xenobiotica 1997, 27, 319-340.
45. Lewis, D. F. V.; Lake, B. G.; Bird, M. G.; Dickins, M.; Eddershaw, P. J.; Tarbit, M. H.; Goldfarb, P. S. Molecular modeling of human CYP2E1 by homology with the CYP102 hernoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the CYP2E1 isoform. Xenobiotica 2000, 50, 1-25.
46. Poulos, T. L. Modelling of mammalian P450s on tine basis of P450cam X-ray crystal structure. Methods Enzymol. 1991, 206, 11-30.
47. Modi, S.; Primrose, W. U.; Boyle, J. M. B.; Gibson, C. F.; Lian, L.-Y.; Roberts, G. C. K. NMR studies of substrate binding to cytochrome P450BM3: Comparisons to cytochrome P450cam. Biochemistry 1995, 34, 8982-8988.
48. Graham-Lorence, S. E.; Peterson, J. A. Structural alignments of P450s and extrapolations to the unknown. Methods Enzymol. 1996, 272, 315-326.
49. Jean, P.; Pothier, J.; Dansette, P. M.; Mansuy, D.; Viari, A. Automated multiple analysis of protein structures: application to homology modeling of cytochromes P450. Proteins 1997, 28, 388-404.
50. Lewis, D. F. Homology modeling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity. Exp. Toxicol. Pathol. 1999, 61, 369-374.
51. Keseru, GM A virtual high throughput screen for high affinity P450cam substrates. Implications for in silico prediction of drug metabolism. J. Comput.-Aided Mol. Des. 2001, 15, 649-657.
52. Islam, S. A.; Wolf, C. R.; Lennard, M. S.; Stemberg, M. J. E. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 1991, 12, 2211-2219.
53. Ellis, S. W.; Smith, G.; Wolf, C. R.; Tucker, G. T.; Woods, H. F. Evidence that Aspartate 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J. Biol. Chem. 1995, 270, 29055-29058.
54. Goldberg, D. E. In Genetic Algorithms; Addison-Wesley: New York, 1989.